CN103462998A - Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer - Google Patents
Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer Download PDFInfo
- Publication number
- CN103462998A CN103462998A CN2013104782978A CN201310478297A CN103462998A CN 103462998 A CN103462998 A CN 103462998A CN 2013104782978 A CN2013104782978 A CN 2013104782978A CN 201310478297 A CN201310478297 A CN 201310478297A CN 103462998 A CN103462998 A CN 103462998A
- Authority
- CN
- China
- Prior art keywords
- neonectrolide
- ulcer
- treating
- day
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of Neonectrolide A in preparing a medicament for treating or preventing dental ulcer, which is disclosed for the first time. The frame model is a brand-new frame model, and Neonectrolide A has a strong activity in treating dental ulcer, has a highlighted substantial characteristic, and is remarkably progressed in treating dental ulcer.
Description
Technical field
The present invention relates to the new purposes of compound N eonectrolide A, relate in particular to the application of Neonectrolide A in preparation treatment or preventing canker sore medicine.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus(1975) investigate 1587 people, prevalence is 20%.As can be seen here, the oral ulcer patient is a very huge colony.The cause of disease complexity of recurrent oral ulceration, still indefinite so far, may infect with viral infection, antibacterial and the factors such as the endocrine regulation of body, immune dysfunction relevant.The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because the topical therapeutic toxic and side effects is lower, the people who has therefore obtained people can.Although the buccal tablets that the part occurred is in recent years used carries, easy to use, mouthfeel and compliance are better, and as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields at aspects such as sterilization, antiinflammatory, pain relievings.
The compound N eonectrolide A the present invention relates to is one and within 2012, delivers (Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012, 14(24) 6226 – 6229.) noval chemical compound, this compound has brand-new framework types, current purposes only suppresses part tumor cell proliferation (Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012, 14(24) 6226 – 6229.), the purposes of the Neonectrolide A the present invention relates in preparation treatment or preventing canker sore medicine belongs to open first.
Summary of the invention
The object of the invention is to, according in existing Neonectrolide A research, not finding that it has the present situation of the report for the treatment of or preventing canker sore, provides the application of Neonectrolide A in preparation treatment or preventing canker sore medicine.
Described compound N eonectrolide A structure is as shown in formula I:
The purposes of the Neonectrolide A the present invention relates in preparation treatment or preventing canker sore medicine belongs to open first, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore are active strong, possess outstanding substantive distinguishing features, be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
The specific embodiment
The preparation method of compound N eonectrolide A involved in the present invention is referring to document (Jinwei Ren, et al., Neonectrolide A, a New Oxaphenalenone Spiroketal from the Fungus Neonectria sp.Organic Letters, 2012,14(24) 6226 – 6229.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound N eonectrolide A tablet involved in the present invention:
Get 5 and digest compound Neonectrolide A and add dextrin 195 grams, mix, conventional tabletting is made 1000.
Embodiment 2: the preparation of compound N eonectrolide A capsule involved in the present invention:
Get 5 and digest compound Neonectrolide A and add starch 195 grams, mix, encapsulatedly make 1000.
Further illustrate its pharmaceutically active below by pharmacodynamic experiment.
The experimental study of test example 1:Neonectrolide A anti-oral ulcer
1, test objective: whether manufacture the oral ulcer model with phenol, give the Neonectrolide A of the certain number of times of oral ulcer rat model every day, observing Neonectrolide A has the effect that reduces ulcer.
2, tested medicine and reagent
Cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol
Animal: the Wistar rat, male, body weight 240～280g, Nanjing Medical University's Experimental Animal Center.
3, test method
Get 50 of rats, male, body weight 240～280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, by the plastic dropper of 90% phenol cotton balls, (internal diameter: 3mm) lower end is flat on the cheek film at the about 1mm of rats with left bicker place, calcination 30min, be shown in the white infringement that this locates about 3mm.Grouping immediately after 24 hours,, divide 5 groups, i.e. model group (4 times/days of adjuvants, containing medicine) by 10 every group; Neonectrolide A high dose group (4 times/days, 0.5mg/ time); Dosage in Neonectrolide A (4 times/days, 0.1mg/ time); Neonectrolide A low dose group (4 times/days, 0.02mg/ time); Positive controls: cydiodine group (4 times/days, 0.5mg/ time).Neonectrolide A and cydiodine buccal tablet be pulverize before use, and administration be take flap coverage as degree.Successive administration 5 days, observe ulcer area size (in the diameter of ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer) next day before administration and after each administration, and first administration to last administration is recorded as respectively 1,2,3,4,5,6 day.The ulcer area size is checked with t, and ulcer healing rate is checked with X2.
4, result of the test
Ulcer area is (table 1) relatively: Neonectrolide A high dose group and model group relatively, play off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Cydiodine group and model group relatively, play off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; In Neonectrolide A, dosage group and model group relatively, play off-test on the 3rd day from administration, and significant difference is relatively arranged corresponding every day; Neonectrolide A low dose group and model group relatively, play off-test on the 5th day from administration, and significant difference is relatively arranged corresponding every day; In Neonectrolide A, dosage group and cydiodine group relatively, play off-test on the 1st day from administration, and significant difference is relatively arranged corresponding every day.
The impact of table 1 on the rat ulcer area
Annotate: compare * p<0.05, * p<0.01 with model group.
Healing rate (table 2): model group and Neonectrolide A low dose group play off-test on the 1st day from administration, and ulcer is healing not; And Neonectrolide A high dose group just had ulcer healing from administration the 4th day, to off-test, reach 90%; The cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In Neonectrolide A, the dosage group, from administration the 5th day, has ulcer healing, to off-test, reaches 40%.
The impact of table 2 on the rat ulcer healing time
Annotate: compare * p<0.05, * p<0.01 with model group.
5, conclusion
Neonectrolide A has the effect of obvious promotion oral ulcer healing.
Claims (1)
1.Neonectrolide the application of A in preparation treatment or preventing canker sore medicine, described compound N eonectrolide A structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104782978A CN103462998A (en) | 2013-10-14 | 2013-10-14 | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013104782978A CN103462998A (en) | 2013-10-14 | 2013-10-14 | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103462998A true CN103462998A (en) | 2013-12-25 |
Family
ID=49788196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013104782978A Pending CN103462998A (en) | 2013-10-14 | 2013-10-14 | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103462998A (en) |
-
2013
- 2013-10-14 CN CN2013104782978A patent/CN103462998A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN1943675A (en) | Tibetan medicinal composition for expectorant, antitussive, antiasthmatic and its preparation method | |
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN103127077A (en) | Application of Aphanamixoid A to dental ulcer treatment or prevention medicine | |
| CN103356549A (en) | Application of Sarcaboside A in medicine for treating or preventing oral ulcer | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN103027918A (en) | Application of Houttuynoid E in preparation of drug for treating or preventing oral ulcer | |
| CN103381160A (en) | Applications of Chukrasone B in medicines used for curing or preventing oral ulcer | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131225 |
|
| WD01 | Invention patent application deemed withdrawn after publication |